New technology designed to speed dystrophin measurement while ensuring consistency Automation of dystrophin measurement will aid development of Sarepta’s Duchenne muscular dystrophy candidates Cambridge, Mass. - Aug 20, 2014 - Sarepta Therapeutics, Inc, a developer of...
Sarepta Enters into Partnership with Flagship Biosciences in Muscular Dystrophy
read more